Clin2
NCT06499025Possibly a fitEnrolling by invitation

T-cell therapy for a type of AML with the AML1-ETO gene

AMLt(8;21)Neoantigen

Treatments studied

CyclophosphamideDecitabine

Part of Blood & lymphatic, Cancer clinical trials.

This trial tests a personalized cell therapy that uses your own immune cells (T cells) to target a specific protein (AML1-ETO) found in certain AML cells. It is for patients whose leukemia has come back or not gone away after standard treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
16 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old
  • You have a type of AML called t(8;21) or persistent AML1-ETO gene after chemotherapy
  • Your HLA type is either A*11:01 or A*02:01 (a blood test will check this)
  • Your leukemia has not responded to or has returned after at least 2 cycles of treatment
  • You have a good performance status (ECOG score of 0 or 1, meaning you can do daily activities)
  • You are willing to have blood drawn to collect cells for the therapy

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07617285Recruiting· Phase 1
CAR-T cell therapy for relapsed or refractory acute myeloid leukemia

This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.

Beijing
NCT07342244Not yet recruiting
A two-step treatment for hard-to-treat acute myeloid leukemia

This study tests a new treatment that uses your own immune cells (called CAR-T cells) to fight leukemia, followed by a stem cell transplant to help rebuild your immune system. It is designed for people with acute myeloid leukemia (AML) that has not gone away or has come back after standard treatment.

Wuhan, Hubei
NCT03222674Not yet recruiting· Phase 1/Phase 2
Multi-target immune cell therapy for acute myeloid leukemia

This trial tests a new type of immune cell therapy that uses your own cells, modified to attack leukemia cells in multiple ways. It aims to find a safe and effective dose for people with acute myeloid leukemia who have not responded to other treatments.

Shenzhen, Guangdong
NCT07645469Recruiting· Phase 1
WT1-targeting T cells with azacitidine for AML

This trial tests a new type of cell therapy for people with acute myeloid leukemia (AML) that has minimal residual disease (small amounts of cancer left after treatment). The therapy uses your own immune cells, modified to target a protein called WT1 on leukemia cells, and combines it with a drug called azacitidine.

Seattle, Washington
NCT07201727Not yet recruiting· Early Phase 1
Car-t cell therapy for relapsed acute myeloid leukemia

This trial tests a new treatment that uses your own immune cells, modified in the lab to find and attack leukemia cells. It's for people with AML that has come back or hasn't responded to standard treatment, and it may be followed by a stem cell transplant to help prevent the cancer from returning.

NCT03326921Recruiting· Phase 1
T cell treatment for leukemia after a bone marrow transplant

This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.

Seattle, Washington

Hear when a new AML trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.